Diagnologix LLC

Company Overview

Diagnologix LLC, founded in 2013 as a spin-out from the University of California, San Diego, is developing microbubble technology for isolation of cells including CTCs, stem cells and immune cells.

Diagnologix’s platform technology uses perfluorocarbon gas-filled immune-tagged microbubbles, which bind to targeted cell types and separates them from blood or buffy coat (the fraction of an anticoagulated blood sample containing most of the white blood cells and platelets) samples.

In September 2019, Diagnologix was awarded a Phase II SBIR (Small Business Innovation Research) grant. The project’s goal is to develop a closed automated system using only a single container to be integrated into a cGMP environment for cell isolation, expansion and manipulation. This project builds on an earlier Phase I project that demonstrated the technical feasibility of manufacturing a simple and cost-efficient system to enrich cells of interest that require multiple markers to identify.

The Phase II work was finished by September 2021. In September 2021, the company received a fast-track SBIR grant titled “Toward GMP production of antigen specific regulatory T cells.”

Company's Business Segments

• Cell-processing Systems : The company develop cell-processing systems to sort, isolate, and manipulate circulating tumor cells (CTCs), stem cells , and immune cells in bulk-volume biological fluids for research and clinical applications.